I continue to find it difficult to understand why some people equate other's comments about being very cautious with Tysabri as "negative"!


If Biogen is so aware of the dangers of Tysabri, then why have they pushed its introduction into the marketplace so fast from the very beginning? They have run into hurdle after hurdle with this drug as more problems surface as each month passes. It's safety has been questioned from the outset and although all drugs have a risk level associated with them, Biogen's method of operation seems to push ahead as fast as they can and worry about the problems afterwards when they show up.

I and others for months have pointed out the concern we have for this drug as it gets used by more and more patients. It isn't being "negative" but simply giving another point of view.

Harry

Harry I do believe you are missing my point. I am not going to debate it here. This is not the place. And I am not going to continue this useless commentary any longer. Sorry...it serves no purpose whatsoever.

Merry Christmas.

The cause of death for this patient is only speculation.

The cause of death could have been PML. While the Tysabri was removed from the system, the immune response may have been delayed/affected by prior methotrexate treatment. I don't know how long this drug may affect immune response.

The cause of death could have been IRIS. Inflamation from the immune response could have worsened the syptoms and resulted in death. Maybe the PLEX should be less aggressive.

The cause of death could have been complications due to the patients rheumatological condition.

The cause of death could have been due to some other hospital or outside acquired infection.

From Biogen's 8-k

" Patient had also received prior therapy with methotrexate for a rheumatological condition. "